HBIO Rasio cepet Harvard Bioscience, Inc.

Serving as the primary valuation tool, this Harvard Bioscience (HBIO) price chart demonstrates the price action of an asset with a coefficient of 0.93. The business relies on the development of high-precision biomedical instruments, providing equipment to universities and laboratories. Revenue is generated through recurring orders and the sale of ancillary materials. Meanwhile, the seamless supply of sensors and components in the US and Europe minimizes the risk of distribution chain disruptions.

For Harvard Bioscience (HBIO), which is developing the precision equipment and laboratory IT systems sector, maintaining operational flexibility while scaling production automation is critically important. Monitoring quick liquidity reflects the company's ability to instantaneously settle obligations using cash and accounts receivable, excluding slow-moving inventories, allowing investors to objectively assess the issuer's real capital stability and financial autonomy.